President Trump made headlines this week when he boasted about acing a cognitive test, comparing himself to two younger Democrats, both of whom are non-white women. The test he was referring to is the Montreal Cognitive Assessment, a 10-minute test commonly used to detect mild cognitive decline and early signs of dementia or Alzheimer’s disease. This test is usually administered to adults experiencing memory problems or those with concerned family members. Trump’s father, Fred Trump, was diagnosed with Alzheimer’s disease, which has a genetic component.
In addition to the cognitive test, Trump mentioned undergoing an MRI, claiming it was “perfect.” However, he did not provide details about the MRI or whether it was related to the cognitive test. Trump’s comments have raised questions about the evaluation of presidents’ cognitive and physical health, with former White House physician Jeffrey Kuhlman emphasizing the importance of a president being in top mental shape to make critical decisions.
On a different note, tech giant Nvidia has been making strides in the healthcare industry by collaborating with various companies to use AI for drug development and in the life sciences. One notable partnership is with pharma giant Eli Lilly to build an “AI factory” using Nvidia’s chips to accelerate drug discovery models and optimize clinical trials. Nvidia has also partnered with Verily, Johnson & Johnson, and Innovaccer to advance healthcare through AI technology.
In the biotech and pharma sector, Novartis recently acquired Avidity Biosciences for $12 billion to gain access to its dystrophy drugs in late-stage trials. This acquisition marks one of the largest in the biotech industry this year. Additionally, London-based GHO Capital raised $2.9 billion for a new healthcare fund focused on biopharma, medtech, and life sciences tools.
In the digital health and AI space, Recursion received a milestone payment of $30 million for developing a whole-genome map of microglial immune cells, while Curve Biosciences raised $40 million to commercialize its software for chronic disease diagnosis and monitoring. These advancements highlight the growing role of AI in revolutionizing healthcare.
On the medtech front, Collaborative Robots (Cobot) has been working with hospitals to deploy robots for various tasks, such as moving linen carts and surgical tools. These robots aim to streamline operations in hospitals and improve efficiency, ultimately benefiting patients and healthcare providers. Additionally, surgeons successfully removed a genetically modified pig kidney from a patient after nine months, marking a significant milestone in organ transplant research.
In the realm of public health and hospitals, the CDC’s Advisory Committee on Immunization Practices (ACIP) has faced layoffs, potentially impacting vaccine policy decisions. Meanwhile, Texas has sued Tylenol maker Kenvue for allegedly deceiving mothers about autism risks. The FDA also issued new draft guidance to accelerate the approval process for biosimilar drugs, aiming to reduce drug costs for patients.
Overall, these developments in healthcare and technology underscore the ongoing innovation and collaboration driving advancements in the industry. From AI-driven drug discovery to robotic assistance in hospitals, the future of healthcare is filled with promise and potential for improving patient outcomes and enhancing medical care.
